Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage ...
Caitlin Fowler took on a lofty charity challenge to go the distance for partner Lucy Stewart who has a rare lifechanging auto ...
9d
B.C. woman with rare autoimmune condition shares expertise in reimagined chapter of Winnie-the-Pooh
Myasthenia gravis affects about 30 out of every 100,000 people in Canada, according to the Myasthenia Gravis Society of ...
UCB, a global biopharmaceutical company, today announced the recipients of its annual UCB Myasthenia Gravis Scholarship,™ awarding 15 scholarships to individuals in the United States who are living ...
UCB S.A. UCBJY UCBJF on Wednesday presented new data at the International Congress on Neuromuscular Diseases 2026 showing ...
Vor Biopharma pivots to telitacicept for autoimmune diseases, backed by $491M cash to 2029. Click here to read an analysis of ...
Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
Leite has received grants or institutional funding from MDUK and Myaware; consulting fees, honoraria, expert testimony payments, and travel support from UCB Pharma and Amgen; participated in advisory ...
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...
New analyses from the Phase 3 Vivacity-MG3 study support the impact of nipocalimab in anti-AChR+a, anti-MuSK+b adult patients with generalised myasthenia gravis (gMG) including those early in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results